Guest post from Ken Christman, MD.
Dr. Charles Denham left a career in radiation oncology to join the “patient safety” movement. He formed his nonprofit Texas Medical Institute of Technology, became editor-in-chief of the Journal of Patient Safety, and found his way to the National Quality Forum, where he co-chaired the NQF Safe Practices Concensus Committee. There, he ardently promoted a skin antiseptic formulation that, according to Dr. Bob Wachter, would be a “home run” for CareFusion, the manufacturer of ChloraPrep.
In January, 2014, CareFusion agreed to pay a $40.1 million fine to settle U.S. Department of Justice charges that paying Dr. Denham $11.6 million constituted a kickback.